The European Health and Digital Executive Agency (HaDEA) has published three Prior Information Notices (PINs) under the EU4Health programme, signalling upcoming calls for tenders in key areas of health innovation for influenza vaccines, mpox vaccine research, and antimicrobial susceptibility testing (AST) devices, contributing to greater pandemic preparedness and antimicrobial resistance (AMR) mitigation.
- Next generation influenza vaccines. HaDEA has issued PIN HADEA/2025/CPN/0008-PIN, outlining a future call for tenders on multiple sourcing framework contracts aimed at speeding up the development and access to innovative influenza vaccines. Indicative budget: EUR 147 951 410 (indicative ceiling for each of the framework contracts to be signed). The call is anticipated to be published in April 2025.
- Rapid point-of-care AST devices to tackle AMR The PIN HADEA/2025/CPN/0006-PIN notice anticipates a call for tenders dedicated to developing rapid antimicrobial susceptibility testing (AST) medical devices. The goal is to significantly reduce the time required for AST results, ensuring timely and targeted treatment decisions in clinical settings. Indicative budget: EUR 12 860 000. The call is anticipated to be published in April 2025.
- Speed up the access to and uptake of a mpox vaccine. The HADEA/2025/OP/0013-PIN about advancing mpox vaccine research aims to strengthen scientific evidence on the immunity provided by the Modified Vaccinia Ankara virus-Bavarian Nordic (MVA-BN) vaccine, focusing on the need, optimal timing and safety of booster a dose. Indicative budget: EUR 4 900 000. The call is anticipated to be published in March 2025.
For more details and updates, please visit the EU Funding and Tenders Portal.